276
Participants
Start Date
October 25, 2017
Primary Completion Date
December 25, 2023
Study Completion Date
March 31, 2026
Gilteritinib
Tablet administered orally once daily.
Cytarabine
Once/twice daily Intravenously (IV)/subcutaneously (SC).
Mitoxantrone
Once daily IV injection.
Etoposide
Once daily IV injection.
G-CSF
Once daily IV/SC injection.
Fludarabine
Once daily IV injection.
Site CN103, Beijing
Site CN108, Beijing
Site CN109, Beijing
Site CN110, Beijing
Site CN131, Beijing
Site CN116, Changchun
Site CN120, Changsha
Site CN119, Fuzhou
Site CN102, Guangzhou
Site CN114, Guangzhou
Site CN121, Guangzhou
Site CN130, Guiyang
Site CN107, Hangzhou
Site CN118, Hefei
Site CN123, Huangpu Qu
Site CN117, Jinan
Site CN133, Lanzhou
Site CN128, Nanjing
Site CN106, Qingdao
Site CN126, Shanghai
Site CN129, Shanghai
Site CN125, Shenyang
Site CN101, Tianjin
Site CN105, Wuhan
Site CN122, Xi'an
Site CN132, Zhangzhou
Site CN113, Zhengzhou
Site CN136, Zhengzhou
Site MY306, Ampang
Site MY305, George Town
Site MY301, Johor Bahru
Site MY304, Kota Kinabalu
Site MY302, Kuala Lumpur
Site MY303, Pulau Pinang
Site RU506, Kemerovo
Site RU504, Krasnoyarsk
Site RU508, Moscow
Site RU509, Moscow
Site RU501, Saint Petersburg
Site RU502, Saint Petersburg
Site RU507, Saint Petersburg
Site SG401, Singapore
Site SG402, Singapore
Site SG403, Singapore
Site TH203, Bangkok
Site TH205, Bangkok
Site TH204, Chiang Mai
Site TH201, Khon Kaen
Site TH202, Khon Kaen
Lead Sponsor
Astellas Pharma Inc
INDUSTRY